Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis
Rosenkranz S, Gutmann L, Has Silemek A, Dorr M, Häußler V, Lüpke M, Mönch A, Reinhardt S, Kuhle J, Tilsley P, Heesen C, Friese M, Brandt A, Paul F, Zimmermann H, Stellmann J
J NEUROL NEUROSUR PS. 2023;94(11):924-933.

The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis exercise studies
Rosenkranz S, Ploughman M, Hvid L, Zimmer P, Erickson K, Stellmann J, Centonze D, Friese M
MULT SCLER J. 2023;29(13):1569-1577.

Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis
Tilsley P, Strohmeyer I, Heinrich I, Rosenthal F, Patra S, Schulz K, Rosenkranz S, Ramien C, Pöttgen J, Heesen C, Has A, Gold S, Stellmann J
J NEUROL. 2023;270(10):4876-4888.

Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No.
Heesen C, Rosenkranz S
MULT SCLER J. 2022;28(6):861-862.

Sarkoidose als Paradebeispiel einer granulomatösen Erkrankung
Oqueka T, Galow S, Simon M, Weidmann A, Stübiger N, Zengin-Sahm E, Sinning C, Krusche M, Ruffer N, Steurer S, Schick-Bengardt X, Sebode M, Horst L, Steinmetz O, Melderis S, Rosenkranz S, Möller K, Jantke H, Klose H
Z RHEUMATOL. 2022;81(7):535-548.

Proposal for Post Hoc Quality Control in Instrumented Motion Analysis Using Markerless Motion Capture: Development and Usability Study
Röhling H, Althoff P, Arsenova R, Drebinger D, Gigengack N, Chorschew A, Kroneberg D, Rönnefarth M, Ellermeyer T, Rosenkranz S, Heesen C, Behnia B, Hirano S, Kuwabara S, Paul F, Brandt A, Schmitz-Hübsch T
JMIR HUM FACTORS. 2022;9(2):.

Treating sarcoidosis-associated progressive multifocal leukoencephalopathy with infliximab
Rosenkranz S, Häußler V, Kolster M, Willing A, Matschke J, Röcken C, Stürner K, Leypoldt F, Tolosa E, Friese M
BRAIN COMMUN. 2022;4(1):.

Neuronal Adenosine A1 Receptor is Critical for Olfactory Function but Unable to Attenuate Olfactory Dysfunction in Neuroinflammation
Schubert C, Schulz K, Träger S, Plath A, Omriouate A, Rosenkranz S, Morellini F, Friese M, Hirnet D
FRONT CELL NEUROSCI. 2022;16:.

Clinical presentation and disease course of 37 consecutive cases of progressive multifocal leukoencephalopathy (PML) at a German tertiary-care hospital: a retrospective observational study
Graf L, Rosenkranz S, Hölzemer A, Hagel C, Goebell E, Jordan S, Friese M, Addo M, Schulze zur Wiesch J, Beisel C
FRONT NEUROL. 2021;12:632535.

Arm Ergometry to Improve Mobility in Progressive Multiple Sclerosis (AMBOS)-Results of a Pilot Randomized Controlled Trial
Heinrich I, Rosenthal F, Patra S, Schulz K, Welsch G, Vettorazzi E, Rosenkranz S, Stellmann J, Ramien C, Pöttgen J, Gold S, Heesen C
FRONT NEUROL. 2021;12:644533.

Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study
Lagrèze W, Küchlin S, Ihorst G, Grotejohann B, Beisse F, Volkmann M, Heinrich S, Albrecht P, Ungewiss J, Wörner M, Hug M, Wolf S, Diem R
LANCET NEUROL. 2021;20(12):991-1000.

Validation of Computer-Adaptive Contrast Sensitivity as a Tool to Assess Visual Impairment in Multiple Sclerosis Patients
Rosenkranz S, Kaulen B, Zimmermann H, Bittner A, Dorr M, Stellmann J
FRONT NEUROSCI-SWITZ. 2021;15:591302.

Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis
Rosenkranz S, Shaposhnykov A, Träger S, Engler J, Witte M, Roth V, Vieira V, Paauw N, Bauer S, Schwencke-Westphal C, Schubert C, Bal L, Schattling B, Pless O, van Horssen J, Freichel M, Friese M
ELIFE. 2021;10:e61798.

Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research
Dalgas U, Hvid L, Kwakkel G, Motl R, de Groot V, Feys P, Op't Eijnde B, Coote S, Beckerman H, Pfeifer K, Streber R, Peters S, Riemann-Lorenz K, Rosenkranz S, Centonze D, Van Asch P, Bansi J, Sandroff B, Pilutti L, Ploughman M, Freeman J, Paul L, Dawes H, Romberg A, Kalron A, Stellmann J, Friese M, Heesen C
MULT SCLER J. 2020;26(11):1303-1308.

Contribution of NAADP to Glutamate-Evoked Changes in Ca2+ Homeostasis in Mouse Hippocampal Neurons
Hermann J, Bender M, Schumacher D, Woo M, Shaposhnykov A, Rosenkranz S, Kuryshev V, Meier C, Guse A, Friese M, Freichel M, Tsvilovskyy V
FRONT CELL DEV BIOL. 2020;8:496.

TRPV4-Mediated Regulation of the Blood Brain Barrier Is Abolished During Inflammation
Rosenkranz S, Shaposhnykov A, Schnapauff O, Epping L, Vieira V, Heidermann K, Schattling B, Tsvilovskyy V, Liedtke W, Meuth S, Freichel M, Gelderblom M, Friese M
FRONT CELL DEV BIOL. 2020;8:849.

Multiple Sklerose und körperliche Aktivität: Deutschlandweite Befragung zu Verhalten, Barrieren und Wünschen von Betroffenen
van der Ven E, Riemann-Lorenz K, Rosenkranz S, Patra S, Heesen C
Neurol Rehabil. 2020;26(3):169-178.

T Cell Repertoire Dynamics during Pregnancy in Multiple Sclerosis
Ramien C, Yusko E, Engler J, Gamradt S, Patas K, Schweingruber N, Willing A, Rosenkranz S, Diemert A, Harrison A, Vignali M, Sanders C, Robins H, Tolosa E, Heesen C, Arck P, Scheffold A, Chan K, Emerson R, Friese M, Gold S
CELL REP. 2019;29(4):810-815.e4.

Bassoon proteinopathy drives neurodegeneration in multiple sclerosis
Schattling B, Engler J, Volkmann C, Rothammer N, Woo M, Petersen M, Winkler I, Kaufmann M, Rosenkranz S, Fejtova A, Thomas U, Bose A, Bauer S, Träger S, Miller K, Brück W, Duncan K, Salinas G, Soba P, Gundelfinger E, Merkler D, Friese M
NAT NEUROSCI. 2019;22(6):887-896.

Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis
Akbulak R, Rosenkranz S, Schaeffer B, Pinnschmidt H, Willems S, Heesen C, Hoffmann B
MULT SCLER RELAT DIS. 2018;19:44-49.

Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosis-a randomized controlled trial
Baquet L, Hasselmann H, Patra S, Stellmann J, Vettorazzi E, Engel A, Rosenkranz S, Poettgen J, Gold S, Schulz K, Heesen C
PEERJ. 2018;6:e6037.

Low clinical conversion rate in clinically isolated syndrome patients - diagnostic benefit of McDonald 2010 criteria?
Rosenkranz S, Kaulen B, Neuhaus A, Siemonsen S, Köpke S, Daumer M, Stellmann J, Heesen C
EUR J NEUROL. 2018;25(2):247-e9.

Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring
Stoessel D, Stellmann J, Willing A, Behrens B, Rosenkranz S, Hodecker S, Stürner K, Reinhardt S, Fleischer S, Deuschle C, Maetzler W, Berg D, Heesen C, Walther D, Schauer N, Friese M, Pless O
FRONT HUM NEUROSCI. 2018;12:226.

Ruxolitinib treatment in a patient with neuromyelitis optica: A case report
Hodecker S, Stellmann J, Rosenkranz S, Young K, Holst B, Friese M, Heesen C
NEUROL-NEUROIMMUNOL. 2017;4(2):e328.

Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis
Briken S, Rosenkranz S, Keminer O, Patra S, Ketels G, Heesen C, Hellweg R, Pless O, Schulz K, Gold S
J NEUROIMMUNOL. 2016;299:53-58.

Autoimmune Enzephalitiden-Assoziierte Antikörper sind entscheidene Marker für Pathogenese und Prognose
Rosenkranz S, Friese M
Info Neurol Psych. 2015;17(10):38-49.

Amyloid-precursor-protein-lowering small molecules for disease modifying therapy of Alzheimer's disease
Rosenkranz S, Geissen M, Härter K, Szalay B, Ferrer I, Vogel J, Smith S, Glatzel M
PLOS ONE. 2013;8(12):e82255.

Letzte Aktualisierung aus dem FIS: 18.04.2024 - 07:06 Uhr